| Study |
Study arms |
Population |
Primary outcome |
Estimated study completion |
| NCT01373216 |
Exenatide vs. no intervention |
38 patients with type 2 diabetes undergoing elective aortocoronary bypass |
Cardiac function – echocardiographic parameters |
April 2014 |
| NCT01254123 (EXAMI) [101, 102] |
Exenatide vs. placebo |
40 patients with first acute myocardial infarction undergoing primary PCI |
Safety |
Unknown |
| NCT01144338 (EXSCEL) |
Exenatide vs. placebo |
14,000 patients with type 2 diabetes |
Time to composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke |
April 2018 |
| NCT01715428 |
Liraglutide |
300 patients with type 2 diabetes |
Carotid intima-media thickness |
December 2015 |
| NCT01179048 (LEADER) |
Liraglutide vs. placebo |
9,340 patients with type 2 diabetes |
Time to composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke |
October 2015 |
| NCT01595789 (AddHope2)[103] |
Liraglutide vs. placebo |
40 patients with coronary artery disease and newly diagnosed type 2 diabetes |
Beta-cell function and left ventricular ejection fraction after 12 weeks |
October 2015 |
| NCT01472640 (LIVE)[104] |
Liraglutide vs. placebo |
240 patients with chronic heart failure with and without diabetes |
Change in left ventricular function |
December 2014 |
| NCT01394952 (REWIND) |
Dulaglutide vs. placebo |
9,622 patients with type 2 diabetes |
Time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke |
April 2019 |
| NCT01147250 (ELIXA) |
Lixisenatide vs. placebo |
6,000 patients with type 2 diabetes who recently experienced an acute coronary syndrome event |
Time to first occurrence of the primary cardiovascular event |
January 2015 |
ELIXA, Evaluation of Lixasenatide in Acute Coronary Syndrome; EXAMI, Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction;
EXSCEL, Exenatide Study of Cardiovascular Event Lowering; GLP-1: glucagon-like peptide-1; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results; PCI, percutaneous coronary intervention; REWIND, Researching Cardiovascular Events with a Weekly Incretin in Diabetes